📰 Actinium News
Actinium News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Actinium. Real-time updates on events, politics, business and more.
February 22, 2024
WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...
October 6, 2023
Weight-loss treatments aren’t the only big deal in medicine. Our 2023 healthcare roundtable explores the best investing opportunities.
October 3, 2023
Indianapolis-based Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma company a pipeline of preclinical and clinical radioligand therapies for cancer. The purchase price is an 87% premium to Point’s closing stock price on Oct. 2, and a 68% premium to the 30-day volume-weighted average price. Shares (NASDAQ:PNT) of Point, also of Indianapolis, rose 84.9%, or $5.67, to close at $12.36 on Oct. ...
June 15, 2023
Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatmentDALLAS, TX / ACCESSWIRE / June 15, 2023 / Nano Imrad
April 21, 2023
NEW YORK, NY / ACCESSWIRE / April 21, 2023 / Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis, and treatment remains challenging. It is a devastating disease
December 8, 2022
WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic
October 11, 2022
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Eckert
June 30, 2022
The International Centers for Precision Oncology (ICPO) Foundation is pleased to announce that its first Maurits W. Geerlings Next Generation Award presentation for Outstanding Research and Contributions
April 12, 2022
BRUSSELS (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM), a developer of targeted radiotherapies, announced Tuesday that it has entered into a license and supply agreement with Immedica Pharma
April 10, 2022
Actinium (ACM) traded down 1.8% against the US dollar during the 1-day period ending at 17:00 PM Eastern on April 10th. Over the last seven days, Actinium has traded 3.6% higher against the US dollar. Actinium has a total market capitalization of $635,538.05 and $22,542.00 worth of Actinium was traded on exchanges in the last […]